• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Safinamide in the treatment of Parkinson's disease.
【24h】

Safinamide in the treatment of Parkinson's disease.

机译：野生胺在治疗帕金森病中。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions could offer a significant advantage. AREAS COVERED IN THIS REVIEW: This review surveys the current treatment strategies for PD. Defining unmet needs and how a new compound - safinamide, which has both dopaminergic and non-dopaminergic actions - might address these. WHAT THE READER WILL GAIN: The reader will gain an understanding of safinamide and its mechanisms of action, including reversible MAOB inhibition and reduced dopamine reuptake with antiglutamatergic effects, and how it may potentially provide improvement of PD motor symptoms with an antidyskinetic effect through its effect on glutamate release. The clinical trial profile of safinamide is reviewed. Early results are promising in terms of improved motor function and reduced 'OFF' time. Additional Phase III trials are now in progress for this adjunctive indication. Finally, the reader will understand the potential role for safinamide in the selection and sequencing of drugs for PD. TAKE HOME MESSAGE: safinamide combines both dopaminergic and non-dopaminergic actions that may add a new dimension to PD treatment options as an adjunct to current drugs. Its efficacy is under active evaluation in Phase III clinical trials.
机译：该领域的重要性：帕金森病（PD）的目前疗法主要针对逆转多巴胺缺乏的后果的运动症状，包括左旋多巴，多巴胺激动剂和单胺氧化酶（MAO）B抑制剂。提供多巴胺能和非多巴胺能动作的新药可以提供显着的优势。本次审查所涵盖的地区：此评论调查目前的PD处理策略。定义未满足的需求以及如何具有多巴胺能和非多巴胺能动作的新化合物 - Safinamide - 可能会解决这些问题。读者将获得的内容：读者将理解Safinamide及其作用机制，包括可逆的MAOB抑制和用抗抑制反应减少多巴胺再摄取，以及通过其效果可以提高PD电机症状的改善关于谷氨酸释放。综述了Safinamide的临床试验简档。早期的结果在改进的电机功能方面是有前途的，并减少“关闭”时间。此次辅助指示正在进行另外阶段III试验。最后，读者将理解Safinamide在Pd药物的选择和排序中的潜在作用。带回家的消息：Safinamide结合多巴胺能和非多巴胺能动作，可以将新尺寸添加到PD治疗方案中作为当前药物的辅助药物。其疗效在III期临床试验中进行了活性评估。

著录项

  • 来源
    《Expert opinion on pharmacotherapy》 |2010年第13期|共8页
  • 作者

    Schapira AH;

  • 作者单位

    University College London Institute of Neurology Department of Clinical Neurosciences Rowland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号